Duncan-Williams Initiates Coverage on Exactech (EXAC) with a Buy
EXAC Hot Sheet
Rating Summary:4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Duncan-Williams initiates coverage on Exactech, Inc. (NASDAQ: EXAC) with a Buy. Price target $24.
Duncan analyst says, "We believe that EXAC has significant defensive- growth characteristics. We believe that the Aging of the Population will drive an increase in the volume for orthopedic related surgical procedures and therefore an increase in demand for EXAC's medical devices. We believe that the total worldwide market for orthopedic products is in excess of $30 billion. We estimate that the worldwide market for knees, hips, and spine products are in excess of $5 billion each."
"Top-line growth that accelerates to the bottom-line: For 2009, our revenue and EPS estimates are $180 million and $0.95 respectively. This represents 11% revenue growth and 9% EPS growth compared to the same period last year. Our 2010 revenue and EPS estimates are $200 million and $1.20 respectively. This equates to 11% revenue growth and 26% EPS growth compared to the same period last year."
Exactech, Inc. (Exactech) develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.
Duncan analyst says, "We believe that EXAC has significant defensive- growth characteristics. We believe that the Aging of the Population will drive an increase in the volume for orthopedic related surgical procedures and therefore an increase in demand for EXAC's medical devices. We believe that the total worldwide market for orthopedic products is in excess of $30 billion. We estimate that the worldwide market for knees, hips, and spine products are in excess of $5 billion each."
"Top-line growth that accelerates to the bottom-line: For 2009, our revenue and EPS estimates are $180 million and $0.95 respectively. This represents 11% revenue growth and 9% EPS growth compared to the same period last year. Our 2010 revenue and EPS estimates are $200 million and $1.20 respectively. This equates to 11% revenue growth and 26% EPS growth compared to the same period last year."
Exactech, Inc. (Exactech) develops, manufactures, markets, distributes and sells orthopaedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians in the United States and internationally.
You May Also Be Interested In
- UPDATE: William Blair Starts EPIQ Systems (EPIQ) at Outperform; Broad Suite of Solutions in Electronic Discovery Sector
- Citi, Oppenheimer, William Blair Starts Acquity (AQ) at Buy/Outperform
- Update - William Blair Initiates Coverage on Acquity Group (AQ) with an Outperform; Solid Performance with Secular Tailwinds
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
